GLP1R and diabetes mellitus: Interestingly, Manitoba exhibited the highest diabetes incidence during the 2020–2021 fiscal year (721 per 100,000), yet this province did not experience the most significant expansion in overall prescriptions or the growth of GLP-1 analogs and SGLT-2 inhibitors [8].